Skip to main content

Table 1 Patient characteristics

From: A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas

Patient Age Gender Diagnosis Status Evaluable? Prior Doxo
1 19 M Mesenchymal Chondrosarcoma RR 1 N Y
2 43 F MFH RR 1 Y Y
3 39 F Leiomyosarcoma Relapse 2 Y Y
4 18 M Rhabdomyosarcoma Relapse 1 Y N
5 9 F Rhabdomyosarcoma RR 2 Y N
6 20 F Rhabdomyosarcoma Relapse 1 N Y
7 63 F Leiomyosarcoma Relapse 2 Y Y
8 21 M Rhabdomyosarcoma RR 1 Y Y
9 70 M Spindle Cell Sarcoma Relapse 2 Y N
10 59 F Leiomyosarcoma RR 1 Y Y
11 57 F Chondrosarcoma Mult Relapse Y N
12 10 M Osteosarcoma RR 1 Y Y
13 43 F Clear Cell Sarcoma Relapse 2 Y N
14 16 M Ewing Sarcoma RR 1 Y Y
15 68 F Leiomyosarcoma RR 1 N N
16 57 F Synovial Sarcoma RR 2 Y Y
17 22 F Mesenchymal Chondrosarcoma Relapse 2 Y Y
18 32 M MPNST Relapse 2 Y Y
19 20 F HGUPS RR 1 Y Y
20 21 F Epithelioid Sarcoma Relapse 1 Y Y
21 42 M Rhabdomyosarcoma Refractory Y N
  1. MFH Malignant fibrous histiocytoma, MPNST Malignant peripheral nerve sheath tumor, HGUPS High grade undifferentiated pleiomorphic sarcoma, RR refractory relapse, Patients in italics were treated at the higher dose of temsirolimus (Dose Level 5)